Trending News

Caught in the Act: Practical and Legal Considerations When Executives’ Office Love Affair Exposed

Florida’s CHOICE Act Becomes Law, Enhancing Certain Non-Compete Agreements

Labor Secretary Lifts Abeyance on OFCCP Disability and Veteran Matters

In Case You Missed It: DOL Prohibited From Collecting Liquidated Damages in Wage & Hour Pre-Litigation Investigations

SEC’s New Concept Release on Foreign Private Issuer Standards

What Regulated Businesses Should Know About the Supreme Court’s Recent NEPA Decision

NEW ATDS BATTLEGROUND: Texas Passes HUGE NEW AMENDMENT to Its State Telemarketing Law Reviving The Risk of Autodialer Cases

Supreme Court Eliminates Heightened Discrimination Standard Under Title VII

Cleaning the Cupboard—Six More Decisions in One Day, and a Largely Harmonious Court - SCOTUS Today

U.S. Supreme Court Holds Majority-Group Plaintiffs Are Not Subject to a Heightened Evidentiary Standard Under Title VII

GlobeNewswire Biotech

Website

www.globenewswire.com

Featured Biotech Press Releases From GlobeNewswire

Cellectar Biosciences Announces Pricing of $6 Million Underwritten Public Offering
Posted On Tuesday, July 01, 2025
Inmagene Doses First Patient in the ADAPTIVE Phase 2b Trial of IMG-007, a Nondepleting Anti-OX40 mAb with an Extended Half-life, in Patients with Moderate-to-Severe Atopic Dermatitis
Posted On Tuesday, July 01, 2025
Processa Pharmaceuticals Provides Portfolio and Business Update
Posted On Tuesday, July 01, 2025
IGM Biosciences Enters into Agreement to Be Acquired by Concentra Biosciences for $1.247 in Cash per Share Plus a Contingent Value Right
Posted On Tuesday, July 01, 2025
GRI Bio Completes Enrollment in Phase 2a Study of GRI-0621 for the Treatment of Idiopathic Pulmonary Fibrosis (“IPF”)
Posted On Tuesday, July 01, 2025
Oragenics, Inc. Announces Pricing of Public Offering of up to $20 Million of Preferred Stock and Warrants
Posted On Tuesday, July 01, 2025
CytoDyn Announces Encouraging Survival Data in Patients with Metastatic Colorectal Cancer Previously Treated with Leronlimab
Posted On Tuesday, July 01, 2025
Celularity Hails New Florida Law Opening Patient Access to Stem Cell Therapies
Posted On Tuesday, July 01, 2025
Outlook Therapeutics Appoints Biopharmaceutical Industry and Commercial Leader Bob Jahr as Chief Executive Officer
Posted On Tuesday, July 01, 2025
Nutriband Inc. added to the Russell Microcap® Index, Russell Microcap Growth® Index, Russell 3000E® Index and Russell 3000E Growth® Index
Posted On Tuesday, July 01, 2025
UK MHRA Approval Received for First-In-Human Trial of Rincell-1, a First-In-Class Regenerative Cell Therapy for Sensorineural Hearing Loss
Posted On Tuesday, July 01, 2025
Achieve Life Sciences Announces Closing of Public Offering of Common Stock and Partial Exercise of Underwriters’ Option to Purchase Additional Securities
Posted On Monday, June 30, 2025
COSCIENS Biopharma Announces Results of Virtual 2025 Meeting of Shareholders
Posted On Monday, June 30, 2025
Avicanna Announces Results of Annual General Meeting
Posted On Monday, June 30, 2025
Aptose Announces Deferral of Interest Payment
Posted On Monday, June 30, 2025
Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Posted On Monday, June 30, 2025
Dyne Therapeutics Announces Proposed Public Offering of Common Stock
Posted On Monday, June 30, 2025
Crinetics to Showcase the Next Generation of Endocrinology Innovation at ENDO 2025 with Eight Presentations From its Deep Pipeline
Posted On Monday, June 30, 2025
Dyne Therapeutics Secures Up to $275 Million in Debt Financing from Hercules Capital
Posted On Monday, June 30, 2025
I-Mab Announces Publication of Givastomig Monotherapy Data in Clinical Cancer Research
Posted On Monday, June 30, 2025
Jupiter Neurosciences Showcases Nugevia™ PWR: Mitochondrial Optimization Supplement Designed to Boost Energy, Endurance, and Recovery
Posted On Monday, June 30, 2025
Tevogen CEO Contributes to Build-Out and First-Year Operations of New Headquarters
Posted On Monday, June 30, 2025
Portal Biotech Raises $35 Million Series A, Leveraging AI to Deliver the World’s First Full-Length Single-Molecule Protein Sequencer
Posted On Monday, June 30, 2025
Mineralys Therapeutics Announces Journal of the American Medical Association (JAMA) Publication of Pivotal Phase 3 Launch-HTN Trial for Lorundrostat
Posted On Monday, June 30, 2025
Aclaris Therapeutics Added to the Russell 2000® and Russell 3000® Indexes
Posted On Monday, June 30, 2025

Print